ALM

Almirall is a leading global pharmaceutical company headquartered in Barcelona, Spain, with a primary strategic focus on medical dermatology. Founded in 1944, the company has evolved from a generalist pharmaceutical firm into a specialized leader in skin health, offering a broad portfolio of treatments for conditions such as psoriasis, atopic dermatitis, and actinic keratosis. Almirall's commercial success is driven by key products like Ebglyss (lebrikizumab), Ilumetri (tildrakizumab), and Klisyri (tirbanibulin). The company maintains a robust R&D pipeline focused on innovative modalities, including biologics and targeted protein degraders, to address high unmet needs in inflammatory skin diseases. Almirall operates globally with a direct presence in over 20 countries and strategic partnerships extending its reach to more than 70 markets.